"Proto-Oncogene Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
| Descriptor ID |
D011518
|
| MeSH Number(s) |
D12.776.624.664.700
|
| Concept/Terms |
Proto-Oncogene Proteins- Proto-Oncogene Proteins
- Proto Oncogene Proteins
- Proto-Oncogene Products, Cellular
- Cellular Proto-Oncogene Products
- Proto Oncogene Products, Cellular
- Proto Oncogene Proteins, Cellular
- c-onc Proteins
- c onc Proteins
- Cellular Proto-Oncogene Proteins
- Cellular Proto Oncogene Proteins
- Proto-Oncogene Proteins, Cellular
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins".
This graph shows the total number of publications written about "Proto-Oncogene Proteins" by people in this website by year, and whether "Proto-Oncogene Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 5 | 1 | 6 |
| 1996 | 7 | 6 | 13 |
| 1997 | 6 | 4 | 10 |
| 1998 | 10 | 4 | 14 |
| 1999 | 10 | 4 | 14 |
| 2000 | 6 | 6 | 12 |
| 2001 | 7 | 8 | 15 |
| 2002 | 14 | 12 | 26 |
| 2003 | 11 | 8 | 19 |
| 2004 | 18 | 13 | 31 |
| 2005 | 10 | 9 | 19 |
| 2006 | 7 | 2 | 9 |
| 2007 | 4 | 5 | 9 |
| 2008 | 3 | 4 | 7 |
| 2009 | 6 | 7 | 13 |
| 2010 | 4 | 3 | 7 |
| 2011 | 11 | 6 | 17 |
| 2012 | 6 | 5 | 11 |
| 2013 | 9 | 12 | 21 |
| 2014 | 10 | 10 | 20 |
| 2015 | 11 | 3 | 14 |
| 2016 | 6 | 4 | 10 |
| 2017 | 13 | 3 | 16 |
| 2018 | 7 | 3 | 10 |
| 2019 | 11 | 5 | 16 |
| 2020 | 7 | 4 | 11 |
| 2021 | 9 | 3 | 12 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 3 | 3 |
| 2024 | 6 | 6 | 12 |
| 2025 | 7 | 2 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins" by people in Profiles.
-
TET2-mutant myeloid cells mitigate Alzheimer's disease progression via CNS infiltration and enhanced phagocytosis in mice. Cell Stem Cell. 2025 Aug 07; 32(8):1285-1298.e8.
-
Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHD. Blood. 2025 Jun 12; 145(24):2813-2827.
-
Folliculin Deletion in the Mouse Kidney Results in Cystogenesis of the Loops of Henle via Aberrant TFEB Activation. Am J Pathol. 2025 Sep; 195(9):1643-1659.
-
Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma. Cancer Lett. 2025 Aug 10; 625:217814.
-
Clonal hematopoiesis of indeterminate potential and incidence of venous thromboembolism in older adults. J Thromb Haemost. 2025 Jul; 23(7):2235-2241.
-
Folliculin depletion results in liver cell damage and cholangiocarcinoma through MiT/TFE activation. Cell Death Differ. 2025 Aug; 32(8):1460-1472.
-
Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition. Nat Commun. 2025 Mar 18; 16(1):2641.
-
Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 02; 220:115308.
-
ERK activation dynamics in maturing oocyte controls embryonic nuclear divisions in Caenorhabditis elegans. Cell Rep. 2025 01 28; 44(1):115157.
-
PRDM16 Enhances Osteoblastogenic RUNX2 via Canonical WNT10b/?-CATENIN Pathway in Testosterone-Treated Hypogonadal Men. Biomolecules. 2025 Jan 08; 15(1).